Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Lurbinectedina con o senza avelumab nel carcinoma a piccole cellule della vescica (LASER)

11 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Uno studio di fase II sulla lurbinectedina con o senza avelumab nel carcinoma a piccole cellule della vescica (LASER)

Background:

Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET.

Objective:

To test lurbinectedin with or without avelumab in people with SCCB or HGNET.

Eligibility:

Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment.

Design:

Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor.

Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects.

Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function.

Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Background:

  • Small cell carcinoma of the bladder (SCCB) is a rare, aggressive form of bladder cancer, accounting for less than 1% of all bladder malignancies.
  • High grade neuroendocrine tumors (HGNET) of the urinary tract are very rare and include both small cell neuroendocrine carcinomas (SCNEC) and large cell neuroendocrine carcinomas (LCNEC).
  • Traditionally regimens drawn from the small cell lung cancer literature (cisplatin and etoposide) are used in the frontline setting, and while initially highly responsive to chemotherapy, responses are generally short lived.
  • There is little evidence to guide therapeutic decisions at time of disease progression.
  • Lurbinectedin is a selective inhibitor of oncogenic transcription that binds preferentially to guanines located in the GC-rich regulatory areas of DNA gene promoters.
  • Lurbinectedin prevents binding of transcription factors to their recognition sequences, inhibiting oncogenic transcription and leading to tumor cell apoptosis.
  • Lurbinectedin was recently approved as a second line agent in small cell lung cancer, where it has shown an overall response rate of 35%.
  • Immune checkpoint inhibitors (ICIs) have become part of the standard of care for small cell lung cancer, and their use in the community for treatment of SCCB has increased.
  • However, ICI use in SCCB is still case reportable in the literature, and no prospective studies have been published to date.

Objective:

-To assess the objective response rate (ORR) of lurbinectedin, either alone or in combination with avelumab, in participants with small cell carcinoma of the bladder (SCCB) or other high grade neuroendocrine tumors (HGNETs) of the urinary tract

Eligibility:

  • Age >= 18 years
  • Histologically confirmed diagnosis of metastatic SCCB or HGNET of the urinary tract
  • Participants must have metastatic disease defined as new or progressive lesions.
  • Participants must have at least one measurable site of disease
  • Participants must have received, be ineligible, or refused prior platinum/etoposide chemotherapy for SCCB or HGNET of the urinary tract.

Design:

  • This is a Phase II, multisite, open label, nonrandomized study with two cohorts.
  • All participants will receive lurbinectedin.
  • Participants without prior ICI exposure will be eligible to receive concurrent avelumab.
  • Treatment will be given in 21-day cycles continuously for up to 10 years or until signs of progression or intolerable side effects.
  • Lurbinectedin will be administered intravenously (I.V.) at 3.2mg/m^2 every 21 days.
  • Avelumab will be administered I.V. at 800mg every 21 days.
  • The accrual ceiling will be set at 35 to allow for a small number of inevaluable participants.

Tipo di studio

Interventistico

Iscrizione (Stimato)

45

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Maryland
      • Bethesda, Maryland, Stati Uniti, 20892
        • Reclutamento
        • National Institutes of Health Clinical Center
        • Contatto:
          • National Cancer Institute Referral Office
          • Numero di telefono: (888) 624-1937
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 120 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

  • INCLUSION CRITERIA:

  • Histologically or cytologically confirmed metastatic small cell carcinoma of the bladder (SCCB) or other high grade neuroendocrine tumors (HGNETs) of the urinary tract (which includes renal pelvis, ureter, and urethra, and excludes neuroendocrine tumors of the prostate). Mixed histologies, with any component including SCCB or HGNETs, are eligible for inclusion.

  • Prior treatment as follows:

    • For Cohort 1: Participants must have received prior ICIs (PD-1 or PD-L1) or be ineligible for treatment with ICIs.
    • For Cohort 2: Participants must be ICI naive but eligible to receive them.
  • Participants must have metastatic disease defined as new or progressive lesions.

  • Participants must have at least one measurable site of disease, per RECIST 1.1.

  • Participants must have received, be ineligible, or refused prior platinum/etoposide chemotherapy for SCCB or other HGNET of the urinary tract. Platinum ineligibility is defined as a CrCl <30, or two or more of the following: CrCl <50-60, ECOG >=2, hearing loss >= grade 2, peripheral neuropathy >= grade 2, New York Heart Association (NYHA) heart failure class >= class III.

  • Age >=18 years.

  • Eastern Cooperative Oncology Group [ECOG] performance status (PS) <=2 (Karnofsky >=60%).

  • Adequate organ and marrow function as defined below:

    • Absolute neutrophil count (ANC) >=1,500/microliter

    • Platelets >=100,000/ microliter

    • Hemoglobin (Hgb) > 9g/dL (erythrocyte transfusions are allowed to achieve acceptable Hgb)

    • Total bilirubin within normal limits with the following exceptions:

      • Participants with tumor involving the liver may have mild to moderate hepatic impairment with total bilirubin <= 1.5 x upper limit of normal (ULN)
      • Participants with known Gilbert disease who have serum bilirubin level <= 1.5 x ULN
    • Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) <=1.5 x institutional ULN

      ---Participants with tumor involving the liver with AST and ALT <= 5.0 x ULN and bilirubin <= 1.5 x ULN may be eligible.

    • Creatinine clearance (CrCl) >= 30 mL/min/1.73 m^2 (glomerular filtration rate [GFR] may be used in place of CrCl. Creatinine clearance or eGFR should be calculated per institutional standard)

    • Creatine phosphokinase (CPK) <= 2.5 x ULN

  • Participants with previously treated brain metastases or central nervous system (CNS) metastases are eligible if they have recovered from any acute effects of radiotherapy and not requiring steroids, and any whole brain radiation therapy or any stereotactic radiosurgery was completed at least 2 weeks prior to initiation of therapy.

  • Human immunodeficiency virus (HIV) positive participants are eligible if on stable dose of highly active antiretroviral therapy (HAART), CD4 counts are > 350 cells/mm^3 and viral load is undetectable.

  • Hepatitis B virus (HBV) positive participants are eligible if they have been treated or are on an appropriate course of antivirals at study entry and with planned monitoring and management according to appropriate guidance including prophylaxis.

  • Hepatitis C virus (HCV) positive participants are eligible if:

    • they are on active HCV therapy at study entry or are on an appropriate course of antivirals without documented clinically significant impaired liver function test or hematologic abnormalities and with planned monitoring and management according to appropriate labeling, or if they are post-treatment for HCV; or
    • they have a negative polymerase chain reaction (PCR).
  • Systemic corticosteroid therapy (defined as >= the equivalent of prednisone 10 mg/day) or other immunosuppressive agents such as azathioprine or cyclosporin must be discontinued at least 1 week prior to treatment initiation for recent short course use (<=14 days) or discontinued at least 4 weeks prior to treatment initiation for long term use (>14 days).

  • Contraception requirements as follows:

Individuals of child-bearing potential (IOCBP) must agree to use a highly effective method of contraception (e.g., intrauterine device [IUD], hormonal, surgical sterilization, abstinence) prior to study entry, for the duration of study participation, and for up to six (6) months after discontinuation of the study drug(s).

  • Individuals able to father a child must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to six (6) months after the last dose of the study drug(s). We also will recommend individuals able to father a child with IOCBP partners to ask the partners to be on an effective birth control (hormonal, intrauterine device (IUD), surgical sterilization). Individuals able to father a child must not freeze or donate sperm within the same period.
  • Nursing participants must be willing to discontinue nursing from study treatment initiation through six (6) weeks after the last dose of the study drug(s).
  • Participants must be able to understand and willing to sign a written informed consent document.

EXCLUSION CRITERIA:

  • Prior investigational drug, chemotherapy, immunotherapy or any prior radiotherapy (except for palliative bone directed therapy) within the past 14 days prior to the first drug administration. Additionally, FDA-approved hormonal therapy for the treatment or prevention of other malignancies (e.g., breast cancer, prostate cancer) may be continued where in the opinion of the investigator stopping such therapies may increase the risk of disease progression. Potential drug-drug interactions with the hormonal agent will be assessed by the enrolling investigator prior to enrollment.

  • Participants previously treated with lurbinectedin.

  • History of anaphylactic allergic reactions attributed to compounds of similar chemical or biologic composition to lurbinectedin or avelumab

  • Symptomatic or untreated CNS metastases

  • For Cohort 2: Active autoimmune disease that might deteriorate when receiving avelumab with the exception of:

    • Diabetes type I, eczema, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment
    • Requirement of hormone replacement with corticosteroids if the steroids are administered only for the purpose of hormonal replacement and at doses <= 10mg of prednisone or equivalent per day
    • Requirement of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation)
    • Physiologic doses of corticosteroids (<= the equivalent of prednisone 10 mg/day). The use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to treatment initiation and on study.
  • Prior organ transplantation including allogenic stem cell transplantation.

  • Participants who have received or will receive a live vaccine within 30 days prior to the first administration of study intervention. Seasonal flu vaccines that do not contain a live virus and locally authorized/approved COVID-19 vaccines are permitted.

  • Pregnant people as evaluated by a positive serum or urine beta-human chorionic gonadotropin (beta-hCG) test

  • Severe uncontrolled intercurrent illness that would limit compliance with study requirements, evaluated by history, physical exam, and chemistry panel.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm 1

Treatment with lurbinectedin

Lurbinectedin is administered IV over 1 hour at 3.2 mg/m^2 on day 1 of each 21-day cycle

Sperimentale: Arm 2

Treatment with lurbinectedin and avelumab

Lurbinectedin is administered IV over 1 hour at 3.2 mg/m^2 on day 1 of each 21-day cycle

Avelumab is administered IV at 800 mg over 1 hour on day 1 of each 21-day cycle

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Objective response rate (ORR)
Lasso di tempo: At every restaging (prior to every 3rd cycle) until the end of the treatment

Percentage of participants by best overall response (e.g., CR, PR, SD, PD) to therapy

At every restaging (prior to every 3rd cycle) until the end of the treatment

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety of lurbinectedin with or without avelumab
Lasso di tempo: From first dose through 90 days after last treatment with the study drug(s)

Adverse events (AEs) will be reported by type and grade of toxicity

From first dose through 90 days after last treatment with the study drug(s)
Clinical benefit rate (CBR)
Lasso di tempo: At every restaging (every 9 weeks) until the end of the study therapy

Percentage of participant who have achieved CR, PR, and SD while on treatment.

At every restaging (every 9 weeks) until the end of the study therapy
Progression-free survival (PFS)
Lasso di tempo: At every restaging (every 9 weeks) until PD

Duration of time from start of treatment to time of progression or death, whichever occurs first

At every restaging (every 9 weeks) until PD
Overall survival (OS)
Lasso di tempo: Day 1 of each cycle, at EoT, at the Safety visits, and every 90 days for up to a total of 10 years after the end of therapy.

Time from the start of treatment that participants are still alive.

Day 1 of each cycle, at EoT, at the Safety visits, and every 90 days for up to a total of 10 years after the end of therapy.
Duration of response (DoR)
Lasso di tempo: At each study visit and at every restaging (every 9 weeks) starting at cycle 3 until PD

Time from start of treatment to disease progression or death in participants who achieve CR or PR

At each study visit and at every restaging (every 9 weeks) starting at cycle 3 until PD

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Andrea B Apolo, M.D., National Cancer Institute (NCI)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 giugno 2024

Completamento primario (Stimato)

1 settembre 2027

Completamento dello studio (Stimato)

1 settembre 2028

Date di iscrizione allo studio

Primo inviato

26 gennaio 2024

Primo inviato che soddisfa i criteri di controllo qualità

26 gennaio 2024

Primo Inserito (Effettivo)

29 gennaio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 novembre 2026

Ultimo verificato

9 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 10001523
  • 001523-C

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

All collected IPD will be shared@@@@@@

Periodo di condivisione IPD

This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review and/or will involve genomic data sharing.

Criteri di accesso alla condivisione IPD

Data from this study may be requested by contacting the PI.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .